There is no bias in terms of clinical variables (estrogen receptor status, progesterone receptor status, HER2 status, patient age, Nottingham grade, or tumor size) between the included patients and the population of all eligible breast cancer diagnoses (Figure 2C-H). This evidence concerns the gene PGR and breast cancer.